Abstract

INTRODUCTION The conventional aortic valve replacement is the treatment of choice for symptomatic severe aortic stenosis. Transcatheter technique is a viable alternative with promising results for inoperable patients. Sutureless bioprostheses have shown benefits in high-risk patients, such as reduction of aortic clamping and cardiopulmonary bypass, decreasing risks and adverse effects.OBJECTIVEThe objective of this study was to experimentally evaluate the implantation of a novel balloon-expandable aortic valve with sutureless bioprosthesis in sheep and report the early clinical application.METHODSThe bioprosthesis is made of a metal frame and bovine pericardium leaflets, encapsulated in a catheter. The animals underwent left thoracotomy and the cardiopulmonary bypass was established. The sutureless bioprosthesis was deployed to the aortic valve, with 1/3 of the structure on the left ventricular face. Cardiopulmonary bypass, aortic clamping and deployment times were recorded. Echocardiograms were performed before, during and after the surgery. The bioprosthesis was initially implanted in an 85 year-old patient with aortic stenosis and high risk for conventional surgery, EuroSCORE 40 and multiple comorbidities.RESULTSThe sutureless bioprosthesis was rapidly deployed (50-170 seconds; average=95 seconds). The aortic clamping time ranged from 6-10 minutes, average of 7 minutes; the mean cardiopulmonary bypass time was 71 minutes. Bioprostheses were properly positioned without perivalvar leak. In the first operated patient the aortic clamp time was 39 minutes and the patient had good postoperative course.CONCLUSIONThe deployment of the sutureless bioprosthesis was safe and effective, thereby representing a new alternative to conventional surgery or transcatheter in moderate- to high-risk patients with severe aortic stenosis.

Highlights

  • The conventional aortic valve replacement is the treatment of choice for symptomatic severe aortic stenosis

  • The bioprosthesis is made of a metal frame and bovine pericardium leaflets, encapsulated in a catheter

  • The sutureless bioprosthesis was deployed to the aortic valve, with 1/3 of the structure on the left ventricular face

Read more

Summary

Introduction

The conventional aortic valve replacement is the treatment of choice for symptomatic severe aortic stenosis. In recent times the transcatheter technique (TAVI) has emerged as a viable and effective alternative to treat high risk or inoperable patients[1]. The proposed benefits of this technology include enhanced implantability, shorter aortic cross-clamp and cardiopulmonary bypass (CPB) times, favourable hemodynamic performance, and easier access for minimally invasive surgery[5,6,7,8]. This approach allows complete removal of the diseased native valve and comprises a suitable alternative to multiple valve procedures or associated coronary

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call